Abstract
Immunocompromised populations are at high risk for severe COVID-19. Vaccine-induced SARS-CoV-2 antibody responses are attenuated in solid organ transplant recipients (SOTRs), and breakthrough infections are more common. Additional SARS-CoV-2 vaccine doses may increase anti-spike antibody titers in some SOTRs, but whether this results in enhanced neutralizing capability, especially versus novel variants of concern (VOCs) that exhibit immune escape and higher infectivity (e.g., the Delta variant), is unclear. Here, we report that a third dose of a SARS-CoV-2 vaccine increases anti-SARS-CoV-2 spike and RBD IgG levels as well as plasma neutralizing capability versus VOCs, including Delta, in some SOTRs. However, anti-spike IgG and neutralizing capability remained significantly reduced compared to fully vaccinated healthy controls. These findings highlight the need for continued study of strategies to improve protection from COVID-19 in immunosuppressed populations as more SARS-CoV-2 VOCs emerge.
Competing Interest Statement
DLS has the following financial disclosures: consulting and speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, Thermo Fisher Scientific. None of the other authors have any relevant competing interests.
Funding Statement
This work was supported by the Ben-Dov family, the Johns Hopkins COVID-19 Vaccine-related Research Fund, the National Cancer Institute (U54CA260491), grants 5T32DK007713 (JLA), F32DK124941 (BJB), and K23DK115908 (JMGW) from the National Institute of Diabetes and Digestive and Kidney Diseases, and grants K24AI144954 (DLS), K08AI156021 (AHK), and R01AI120938S1 (AART) from the National Institute of Allergy and Infectious Disease.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
SOTR participants were enrolled in a national prospective, observational cohort: COVID-19 Antibody Testing of Recipients of Solid Organ Transplants and Patients with Chronic Diseases, Johns Hopkins IRB00248540. Healthy control participants were enrolled under Johns Hopkins IRB00027183.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Reasonable requests to the corresponding author for de-identified data will be granted.
